Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of Cpn10 in rheumatoid arthritis
ACTRN12609000078257Phase 2Terminated
- Sponsor
- Cbio
- Start
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of ala-cpn10 in rheumatoid arthritis (RA) (2 arms), sponsored by Cbio. Primary endpoint: Percentage of participants maintaining ACR20 response. Started Jan 2009; status: terminated.
02
Drugs
ala-cpn10
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12609000078257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000078257.